RELLINGEN, Germany - Viromed Medical AG (“Viromed”; ISIN: DE000A3MQR65), a medical technology company specializing in cold plasma technology, has provided a strategic update on its operational orientation. The company remains committed to sustainable, technology-driven growth in the international MedTech market, concentrating on the development of innovative medical devices and translational research for severe respiratory diseases, particularly ventilator-associated pneumonia (VAP).
Over the past two years, Viromed has developed two novel cold plasma medical devices: ViroCAP®, a device for medical wound healing, and PulmoPlas®, a globally unique cold plasma system for applications in pneumology and respiratory tract infections. The company emphasizes that PulmoPlas® serves as a next-generation technological platform with potential for scaling across multiple medical indications.
In the research domain, Viromed has established a high-performance scientific consortium comprising Hannover Medical School (MHH), the Helmholtz Centre for Infection Research (HZI) in Braunschweig, and the Leibniz Institute in Jena. This network brings together expertise in infectiology, pneumology, and translational research to develop novel therapeutic approaches for respiratory tract diseases. Comprehensive publication of results by MHH and HZI is expected at the end of January 2026.
For technological development, Viromed collaborates closely with Relyon Plasma, a subsidiary of TDK. Additionally, international partnerships in Europe, Korea, and Turkey have been established to support future market entry, underscoring the global relevance of the technology.
Due to the strategic focus on research, development, and international market structures, Viromed deliberately refrains from communicating short-term operational updates. The company’s communication strategy emphasizes reporting substantial and relevant milestones to support long-term, sustainable corporate development. Viromed’s research and development programs are aligned with medical benefit, clinical relevance, and sustainable market potential.
Viromed is recognized as a pioneer in pneumological research and plasma technology. The company believes its innovation work has the potential to shape future therapeutic approaches for severe respiratory infections. According to its own assessment, Viromed will play a significant role in the global fight against pathogenic germs in the coming years, particularly with PulmoPlas®.
Furthermore, Viromed has successfully navigated new regulatory hurdles for the approval of ViroCAP® over the past 18 months, with market acceptance and demand already very high.
More information is available at www.viromed-medical-ag.de.
